KDC-MN-048 – Kodiac biolabs

Plain-language summaryIntrigue 48 / 100

Tacrine, sold as Cognex, was the first FDA-approved Alzheimer disease medication (1993). It is rarely prescribed today owing to hepatotoxicity, but remains a research reference compound for cholinesterase inhibition. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

31/100

Historically foundational AChE inhibitor, clinically obsolete, retained only as a pharmacological probe and hybrid-molecule scaffold

Look, tacrine holds a specific place in pharmacological history. It was the compound that proved cholinesterase inhibition could work in Alzheimer disease. That was 1993. The question in 2026 is what it offers a researcher today, and the honest answer is: narrow but real probe utility, not much else.

The mechanism story is more interesting than people give it credit for. Tacrine isn’t a clean AChE inhibitor the way donepezil is; the aminoacridine scaffold also hits BChE and picks up weak NMDA receptor antagonism and modest sodium channel blockade. For researchers studying multi-target directed ligands (MTDL) in the AD space, that profile matters. Tacrine hybrids with memantine, with galantamine, with various natural product fragments have been a minor but productive research thread going back to the early 2000s. The scaffold is a legitimate template for MTDL design, and thats where we think the contemporary bench value actually lives.

What we don’t like is everything else about it as a primary research target. The hepatotoxicity is dose-related and reversible on discontinuation in most cases, yes, but it means roughly half of patients in the original trials developed clinically significant ALT elevation requiring monitoring or drug discontinuation. That’s not a side-effect profile anyone is trying to rehabilitate for clinical use when donepezil, rivastigmine, and galantamine all exist. The translational signal, real and FDA-validated, is essentially historical now. Nobody is running a new tacrine arm in a clinical study in 2026.

Evidence quality is genuinely solid in one narrow sense: this compound cleared FDA approval with multiple phase 3 trials, establishing a regulatory and clinical record that most research compounds never approach. But the evidence is old, effect sizes were modest by modern standards, and the safety signal ultimately drove market withdrawal in 2013 after declining prescriptions made the compound commercially unviable. We score evidence at 65 here, crediting the actual clinical program, not the contemporary relevance of the data.

Novelty is essentially zero. The mechanism is mature, the compound is decades old, the literature is not growing in any meaningful direction. Differentiation gets punished hard because better-tolerated AChE inhibitors have replaced tacrine everywhere that matters, except in enzyme kinetics assays and hybrid-molecule research where it functions as a reference standard.

Honestly, if your research program is in cholinesterase pharmacology or MTDL design for neurodegeneration, tacrine is a legitimate template and a useful comparator. That’s real. But it’s not a compound a serious investigator would prioritize as a primary target right now, and scoring it higher than that would misrepresent what the library is for.

Novelty: 10
Mechanism promise: 22
In-category differentiation: 18
Evidence quality: 65
Translational signal: 40
Research bench value: 52

Rationale Tacrine’s score is dragged down by near-zero novelty and clear clinical obsolescence driven by hepatotoxicity; surviving research value is narrow, living in its role as a reference compound and MTDL scaffold rather than as a therapeutic lead worth pursuing.

Aminoacridine acetylcholinesterase inhibitor

The first FDA-approved Alzheimer disease therapy (1993), withdrawn for hepatotoxicity but historically important and retained as a research probe.

Abstract

Tacrine (Cognex, 1,2,3,4-tetrahydroacridin-9-amine; CAS 321-64-2; molecular formula C13H14N2; molecular weight 198.27) is the first FDA-approved cholinesterase inhibitor for Alzheimer disease, granted approval in 1993 and subsequently withdrawn from the US market in 2013 due to hepatotoxicity (approximately 50 percent of patients developed clinically significant ALT elevation requiring monitoring or discontinuation). The compound is a non-selective reversible AChE and BChE inhibitor based on an aminoacridine scaffold. Mechanism includes additional weak NMDA receptor antagonism and modest sodium channel blockade, distinguishing the pharmacology from the more selective subsequent AChE inhibitors. The historical significance of tacrine is substantial; the compound established cholinesterase inhibition as a viable therapeutic strategy for Alzheimer disease and led to development of the more tolerable second-generation agents. The compound retains research utility as a pharmacological probe and AChE reference compound. Pharmacokinetics: short half-life (3 to 4 hours), four-times-daily dosing required in the marketed formulation. Hepatotoxicity is dose-related and reversible on discontinuation in most cases.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-048Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-048

Tacrine

Abstract

Read the full monograph